StockNews.com initiated coverage on shares of Biocept (NASDAQ:BIOC – Get Rating) in a research note published on Saturday morning. The firm issued a hold rating on the medical research company’s stock.
Several other research analysts have also recently commented on the stock. Brookline Capital Management cut shares of Biocept from a buy rating to a hold rating in a report on Friday, January 6th. Maxim Group lowered shares of Biocept from a buy rating to a hold rating in a report on Friday, April 14th.
Biocept Price Performance
NASDAQ:BIOC opened at $0.26 on Friday. The firm has a market cap of $4.54 million, a PE ratio of -0.13 and a beta of 0.92. Biocept has a 12 month low of $0.24 and a 12 month high of $1.75. The company has a quick ratio of 2.83, a current ratio of 2.97 and a debt-to-equity ratio of 0.14. The company’s 50-day moving average price is $0.34 and its two-hundred day moving average price is $0.53.
Institutional Investors Weigh In On Biocept
Biocept Company Profile
Biocept, Inc is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.
- Get a free copy of the StockNews.com research report on Biocept (BIOC)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are Buying
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.